SIMPROVA
LIVE

Serial Number

79281294

Owner

Eiken Kagaku Kabushiki Kaisha

Attorney

Holly M. Ford Lewis

Filing Date

Oct 29, 2019

Add to watchlist:

No watchlists yet
View on USPTO

SIMPROVA Trademark

Serial Number: 79281294 • Registration: 6344064

SIMPROVA is a trademark filed by Eiken Kagaku Kabushiki Kaisha on October 29, 2019. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 10 (Medical Apparatus). The application is currently registered and active.

Owner Contact Info

Eiken Kagaku Kabushiki Kaisha (26 trademarks)

Bunkyo-Ku, Tokyo , JP

Entity Type: 03

Trademark Details

Filing Date

October 29, 2019

Registration Date

May 11, 2021

Published for Opposition

February 23, 2021

Goods & Services

Downloadable computer software used for medical examinations and diagnoses; computer hardware for data processing for scientific research or medical purposes; downloadable computer software for data processing for scientific research or medical purposes; computer programs, recorded, for the analysis of biological samples or microorganisms for scientific, research, or medical purposes; computer programs, downloadable, for the analysis of biological samples or microorganisms for scientific, research, or medical purposes; laboratory experimental machines and apparatus for the analysis of biological samples or microorganisms for scientific research purposes; laboratory apparatus and instruments for the analysis of biological samples or microorganisms for scientific research purposes; laboratory apparatus and instruments, namely, gene amplifiers; laboratory devices for detecting genetic sequences; molecular probes for scientific purposes other than for medical or veterinary purposes

Diagnostic reagents for medical or veterinary purposes; diagnostic preparations for medical or veterinary purposes; reagents for use in medical genetic testing; reagents for use in veterinary genetic testing; nucleic acid-based reagents for medical or veterinary use; diagnostic preparations for medical or veterinary purposes, namely, nucleic acids, marking reagents, buffer chemicals, aqueous and non-aqueous solutions of primary, secondary and tertiary alcohols, salts, distilled water, purified water, and magnetic particles in fluid form; diagnostic preparations for medical or veterinary purposes, namely, materials for reaction vessels for purification, lysis, modification and manipulation of biological samples or microorganism, and for the performance of marking, separation, isolation, purification, amplification and analytical methods for biopolymers, in particular nucleic acids, enzymes, proteins, macro molecules and biologically active substances for separation, analysis and purification of biological and biochemical compounds; diagnostic preparations for medical or veterinary purposes, namely, chemical, biochemical and biotechnological products, and kits comprising products for medical or veterinary purposes, namely, chemical, biochemical and biotechnological products for sample preparation, purification, lysis, modification and manipulation of biological samples or microorganism, and for the performance of marking, separation, isolation, purification, amplification and analytical methods for biopolymers, namely, nucleic acids for medical and veterinary medical purposes, for detecting pathogens, genetic information and conditions of the human body

Chemical reagents for laboratory or research purposes, other than for medical or veterinary purposes; chemical reagents, other than for medical or veterinary purposes; chemicals for use in industry and science; diagnostic reagents, other than for medical or veterinary purposes; diagnostic preparations, other than for medical or veterinary purposes; chemical reagents for use in genetic research; nucleic acid-based reagents, other than for medical or veterinary purposes; chemical and biochemical preparations for industrial or scientific purposes, other than for medical or veterinary purposes; diagnostic preparations, other than for medical or veterinary purposes, namely, nucleic acids reagents, buffer solution, aqueous and non-aqueous solutions of alcohols, salts, distilled water, purified water, silica in powdered or granulated form, and magnetic particles in fluid form; chemical materials for reaction vessels for purification, lysis, modification and manipulation of biological samples or microorganism, and for the performance of marking, separation, isolation, purification, amplification and analytical methods for biopolymers, in particular nucleic acids for separation, analysis and purification of biological and biochemical compounds, none of the foregoing for medical or veterinary purposes; reagents and solvents for sample preparation for purification, lysis, modification and manipulation of biological samples or microorganism, and for the performance of marking, separation, isolation, purification, amplification and analytical methods for biopolymers, in particular nucleic acids for separation, analysis and purification of biological and biochemical compounds, none of the foregoing for medical or veterinary purposes; kits comprising chemical, biochemical and biotechnological products for preparation, purification, lysis, modification and manipulation of samples, and for the performance of marking, separation, isolation, purification, amplification and analytical methods for biopolymers, in particular nucleic acids, including nucleic acids made from biological and biochemical sample material, for separation, analysis and purification of biological and biochemical compounds, none of the foregoing for medical or veterinary purposes; reagent paper, other than for medical or veterinary purposes

Diagnostic apparatus for medical purposes for the analysis of biological samples; fully automated nucleic acid-based reading and analysis medical instrument for rapid diagnostic of infections and diseases at point-of-care for personalized healthcare; genetic testing apparatus for medical or veterinary diagnostic use; clinical and medical diagnostic instruments, namely, nucleic acid analyzer; biological sample collection devices in the nature of medical devices for obtaining body fluid samples; medical specimen cups; disposable devices for analysis of biological samples for medical purposes; molecular probes for medical and veterinary medical purposes

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
Dec 12, 2024 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Sep 20, 2021 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Aug 25, 2021 FICS
FINAL DISPOSITION PROCESSED
Aug 25, 2021 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Aug 11, 2021 FICR
REGISTERED-PRINCIPAL REGISTER
May 11, 2021 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 23, 2021 NPUB
PUBLISHED FOR OPPOSITION
Feb 23, 2021 PUBO
NOTIFICATION PROCESSED BY IB
Feb 20, 2021 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Feb 3, 2021 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Feb 3, 2021 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 3, 2021 NONP
ASSIGNED TO LIE
Jan 19, 2021 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 19, 2021 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 14, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 14, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 14, 2021 TROA
ATTORNEY REVIEW COMPLETED
Nov 30, 2020 ATRV
CORRECTION FROM IB ENTERED - ATTORNEY REVIEW REQUIRED
Nov 21, 2020 CREV
CORRECTION TRANSACTION RECEIVED FROM IB
Sep 18, 2020 CRCV
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Sep 8, 2020 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Sep 8, 2020 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Sep 8, 2020 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Sep 8, 2020 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Sep 8, 2020 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Sep 8, 2020 COAR
REFUSAL PROCESSED BY IB
Aug 29, 2020 RFNT
NON-FINAL ACTION MAILED
Jul 15, 2020 CNRT
NON-FINAL ACTION WRITTEN
Jul 14, 2020 CNRT
CORRECTION FROM IB ENTERED - ATTORNEY REVIEW REQUIRED
Jun 23, 2020 CREV
CORRECTION TRANSACTION RECEIVED FROM IB
Jun 19, 2020 CRCV
REFUSAL PROCESSED BY IB
May 15, 2020 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Apr 17, 2020 RFCS
REFUSAL PROCESSED BY MPU
Apr 17, 2020 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Apr 2, 2020 RFCR
NON-FINAL ACTION WRITTEN
Apr 1, 2020 CNRT
APPLICATION FILING RECEIPT MAILED
Mar 31, 2020 MAFR
ASSIGNED TO EXAMINER
Mar 25, 2020 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 25, 2020 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Mar 23, 2020 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
Mar 19, 2020 REPR